Skip to content

A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01553643
Enrollment
80
Registered
2012-03-14
Start date
2010-01-31
Completion date
Unknown
Last updated
2012-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Arterial Stenosis

Keywords

Huang-Chi-Wu-Wu-Tang, Intracranial arterial prominent stenosis

Brief summary

Intracranial arterial prominent stenosis (IAPS) is one of main cause of stroke especially in Asia. Although antiplatelet aggregative or anticoagulant agent and even surgical operation are used to treat patients with IAPS, the incidence of stroke occurrence still remains high. In addition, symptomatic IAPS most common cause continuous deterioration, thus, increase the incidence of stroke. Therefore, there is a good method to reduce the inceidence of stroke that is to prevent the progressive deterioration of IAPS. Huang-Chi-Wu-Wu-Tang is made of Astrgalus membranaceus (Fisch.) Gge , Paeonia lactiflora Pall , Cinnamom Twig , Zingiber officinale Rose , Ziziphus jujube Mill , and can treat hemiplegia in the traditional Chinese medicine writings. Astragaloside IV is a component of Astrgalus membranaceus, may reduce th cerebral infarction area in middle cerebral arterial occlusion mice. The investigators previous studies have known that paeoniflorin that a component of Paeonia lactiflora Pall can decrease the cerebral infarction area and neurological deficit in middle cerebral arterial occlusion rats. Therefore, the purpose of the present study was to investigate the effect of Huang-Chi-Wu-Wu-Tang on patients with IAPS.

Interventions

DRUGChinese Herb Huang-Chi-Wu-Wu-Tang

Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day

DRUGplacebo

at a rate of 3g two times per day

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
41 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Had received Transcranial Doppolar Sonography. 2. Age \>40 years old. 3. Gender: Male or female. 4. The subject or their legal representative gave written informed consent to participate. 5. Meet with one of the two Transcranial Doppolar Sonography results below: * The evaluated standard of MCA M1 stenosis of 50-99% are as follows: * PSV \>140 cm/s * MFV \>100 cm/s * The evaluated standard of BA stenosis of 50-99% are as follows: * PSV \>100 cm/s * MFV \>60 cm/s

Exclusion criteria

1. Refused to sign the Informed Consent Form. 2. Too irritable to accept the evaluation. 3. Age ≦40 years old. 4. Major diseases such as Myocardial Infarction、Heart failure、Chronic pulmonary obstructive disease(COPD)with dyspnea、Liver failure or Renal failure. 5. Pregnancy or breast-feeding.

Design outcomes

Primary

MeasureTime frame
Primary outcome measure was the improvement hemodynamics at intracranial vessels in the M1 segment of middle cerebral artery (MCA) or basilar artery (BA) shown in transcranial color-coded sonography (TCCS).3 years(all patients)

Countries

Taiwan

Contacts

Primary ContactChung Hsiang Liu, MD.
greengen@gmail.com886-4-22052121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026